Syndax (SNDX) Pharmaceuticals announced the appointment of Dr. Nicholas Botwood to the role of Head of Research and Development and Chief Medical Officer. Dr. Botwood brings to Syndax over 25 years of industry experience, most recently serving as the Head of Worldwide Medical Oncology at Bristol Myers Squibb, where he oversaw all medical activities in its oncology portfolio, including new asset launches, data generation, medical education and commercial strategy. Dr. Botwood will drive Syndax’s R&D strategy and development, succeeding Dr. Neil Gallagher, who is departing to pursue other opportunities.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX: